70 results about "Immune gene" patented technology

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

The invention discloses a kit for detecting a capripoxvirus serum antibody based on a synthetic peptide. A preparation method of the kit comprises the following steps of 1, designing a short-peptide aiming at a capripoxvirus main immunogene P32, 2, synthesizing a peptide fragment by a conventional peptide synthesis technology, 3, preparing the kit for detecting a capripoxvirus serum antibody based on a synthetic peptide, and 4, optimizing conditions and finishing the preparation of the kit for detecting a capripoxvirus serum antibody. A coating antigen adopted by the kit is an external synthetic immunoactive peptide fragment, reduces the danger of totvirus use and prevents virus diffusion and escape. The synthetic peptide adopted by the kit has high purity, has immunological characteristics similar to capripoxvirus particles, and can replace capripoxvirus particles and be used as an antigen for detection and thus the kit realizes sensitive, specific, safe and reliable detection of a capripoxvirus serum antibody.

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera Ileibacterium and Dubosiella, including their species I. valens (I. valens) and Dubosiella newyorkensis (D. newy), respectively, and closely related OTUs within the family Erysipelotrichaceae that resemble either Ileibacterium spp. or Dubosiella spp. with 90% 16S rRNA sequence identity, for modulating weight and intestinal inflammation and immunity (including modulating intestinal immune gene expression such as, e.g., modulating expression of RORγT, IL-17A, IL-17F, RegIIIγ, Relmβ, and Defβ), as well as for treatment and diagnosis of (i) obesity and related conditions such as metabolic syndrome and diabetes mellitus; (ii) allergic and autoimmune diseases, and (iii) gastrointestinal disorders (such as, e.g., inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and celiac disease).

The invention discloses an immune repertoire biological information analysis process based on molecular markers. In the process, single-chain immune globulin genes with the same sequence are selected,and primers and UMI sequences with the same structure are added to 3' ends or 5' ends of the selected single-chain immune globulin genes; after addition is completed, PCR amplification is performed on the immune genes to obtain a test sequence, and the test sequence is filtered; after filtering, the UMI sequence carried by the immune genes is corrected by establishing a directed acyclic tree, then the immune genes marked by the corrected UMI sequence are corrected, and the corrected immune genes are assembled; and finally the assembled immune genes are subjected to statistical analysis and reporting. According to the process, through correction of UMI and correction of the immune genes, the influences of amplification errors and sequencing errors on immune gene sequencing are effectivelyremoved, and the accuracy of sequencing data is improved.

A super-antigen immune gene treater for liver cancer is characterized by that the liver cancer cell specific regulation sequence mediated super-antigen moleculae and co-stimulation moleculae are target expressed in liver cancer cells to specifically enhance the immunogenicity of cancer cell and the recognition action to immunoeffect cells. after the treater is injected to cancer region, it can effectively kill cancer cells.

The invention discloses application of a group of immune-related molecular markers in tissues identified based on a TCGA database in esophageal cancer prognosis. The application specifically comprises the following steps: establishing an immune gene prognosis model related to esophageal cancer prognosis; the method for establishing the model comprises the following steps: step 1, collecting and processing data; step 2, screening differentially expressed genes; and step 3, identifying differentially expressed immune related genes; step 4, performing transcription factor analysis and construction of a transcription factor immune differential expression gene regulation and control network; step 5, performing survival analysis; and step 6, establishing a prognosis risk index evaluation model based on esophageal cancer immune related genes.

The invention relates to an epinephelus coioides interferon IFNgamma1 gene, a protein coded by the gene and an application of the protein in preparing a novel immunopotentiator. According to the invention, an opened reading frame of the IFNgamma1 gene is cloned from head-kidney RNAs (Ribonucleic Acid) of epinephelus coioides through a method of screening a genome database and designing specific primer amplification. The nucleotide sequence of the gene is shown as SEQIDNO:2. The amino acid sequence of the protein coded is shown as SEQIDNO:1. Through initial verification, the epinephelus coioides interferon IFNgamma1 protein can induce associated expression of immunogenes and can be developed to natural immunopotentiators or immunologic adjuvants for fishes.

The present invention relates to a non-PCR (polymerase chain reaction) process, particularly a transcription-based amplification method, for amplifying and cloning sequences containing a variable domain sequence such as an immunoglobulin variable domain sequence from the immunological gene repertoire. The present invention comtemplates the expression of antibody library in either in an in vivo expression vector or in an in vitro transcription/translation system. Isolation of a gene coding for a receptor having the ability to bind a preselected ligand and receptors produced by the gene isolated by the method is also contemplated.

The invention relates to the field of data mining in bioinformatics, in particular to a multi-source data fusion framework for revealing a breast cancer immune escape regulation mechanism. The framework is implemented mainly according to the following steps of: (1) collecting related data of breast cancer samples and normal samples; (2) clustering the breast cancer samples by using NMF (Non-negative Matrix Factorization) to obtain sample subgroup types; (3) comparing the breast cancer samples with the normal samples obtained from GTEx, and finding out differentially expressed related genes; (4) designing a regulation and control analysis algorithm based on ATAC-SEQ data to find immune related genes; (5) verifying the relationship between the TF and the immune gene by using five general databases; and (6) analyzing whether the immune gene obtained according to the framework affects the survival of the patient. The invention provides a multi-source data fusion framework for revealing a breast cancer immune escape regulation mechanism, and the framework has important significance for researching drug relocation and realizing precise medical treatment. The biological significance of the research process and the research result can be effectively improved. More importantly, the single-sample law analysis method can be used for deeply exploring the heterogeneity of a tumor, and has important significance on precise medical practice.

The invention discloses application of recombinant vibrio parahaemolyticus flagellin in improvement of fish immunity. It is found that the recombinant vibrio parahaemolyticus flagellin can induce expression of related immune genes and participate in activation of corresponding immune signal channels, the immunity of fishes is remarkably improved, the recombinant vibrio parahaemolyticus flagellin is expected to be developed into a natural fish immunopotentiator or immunologic adjuvant, and then fish diseases caused by vibrio parahaemolyticus are prevented or treated. Therefore, the recombinantvibrio parahaemolyticus flagellin has a good application prospect in improving fish immunity and preparing a fish immunopotentiator or immunologic adjuvant.

The invention relates to a N protein gene of duck-origin coronavirus ZZ2004, and a clone method and application thereof. The N protein gene sequence has the overall length of 1230 bp, and codes N proteins of 409 amino acid residues. The virus sequence with higher homology is found through random PCR, a pair of specific primers is designed by using the sequence as the template and the corresponding fragments are amplified, and then the fragments are respectively connected with a pMD18-T carrier to clone the N protein gene of the virus. Due to that the N gene is an important immune gene and has important effect in the aspects of cellular immunity, humoral immunity and local immunity. The research of the N gene of the invention favors the discovery of the IBV heteromorphosis regularity, the distinguishing of the different serotypes and the further development of novel genetic engineering vaccine, and plays important role in the effective prevention of the IBV.

The invention discloses recombinant rabies viruses BNSP-CDV-F and BNSP-CDV-H in which canine distemper virus main immune genes are embedded. The recombinant viruses take a rabies virus strain SAD-B19as a framework, CDV-F and CDV-H genes shown in SEQ ID NO.1 and SEQ ID NO.2 are separately inserted between an N gene and P gene of a recombinant plasmid SAD-19 full-length cDNA, and finally recombinant rabies virus strains BNSP-CDV-F and BNSP-CDV-H are saved through a reverse genetic operation technology. The recombinant viruses BNSP-CDV-F and BNSP-CDV-H can express fusion protein and hemagglutinin protein of canine distemper viruses; after a vaccine prepared by mixing the recombinant viruses is used for immunizing animals, a great number of anti-rabies virus antibodies and main immune gene antibodies resistant to the canine distemper viruses can be induced and generated. The cost of the vaccine can also be reduced, and the recombinant viruses BNSP-CDV-F and BNSP-CDV-H have a good application and popularization prospect.